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The ﬁeld of non-coding RNAs (ncRNAs) encompasses a wide array of RNA classes that
are indispensible for the regulation of cellular activities. However, de-regulation of these
ncRNAs can also play key roles in malignant transformation and cancer cell behavior. In this
article we survey a select group of microRNAs and long ncRNAs that appear to contribute
in keys ways to the development of acute and chronic leukemias, as well as contribute to
their diagnosis, prognosis, and potentially, their treatment.
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INTRODUCTION
Non-coding RNAs (ncRNAs) are regarded as regulators of cell
cycle progression, proliferation, and fate. There are numerous
classes of ncRNAs, including very long ncRNAs, PIWI-associated
ncRNAs, and small interfering RNAs. However few have been
described with respect to hematopoiesis. Here we review the cur-
rent understanding of the role of microRNAs (miRNA) and long
non-coding RNAs (lncRNAs) in the pathogenesis of acutemyeloid
leukemia (AML), acute lymphoblastic leukemia (ALL), chronic
lymphocytic leukemia (CLL), and chronic myeloid leukemia
(CML).
REGULATORY microRNAs IN LEUKEMIA
MicroRNAs, negative regulators of gene expression, are initially
transcribed as long primary miRNAs by RNA polymerase II, and
subsequently processed by the nuclear ribonuclease Drosha and
the cytoplasmic dsRNA-speciﬁc endonuclease Dicer. Mature miR-
NAs, averaging 22 nucleotides, associate with the RNA induced
silencing complex (RISC) that aids in generating their repres-
sive functions. The most efﬁcient miRNA targeting is achieved
by mature miRNAs binding to the 3′-untranslated regions (UTR)
of target messenger RNAs (mRNA) leading to translational inhi-
bition or mRNA cleavage (Zhang et al., 2007). miRNAs also
bind within coding regions and 5′UTRs, through which addi-
tional regulation of mRNA translation can be mediated (Figure 1;
Ørom et al., 2008; Tay et al., 2008). miRNAs have garnered
much interest due to their role as post-transcriptional regulators
of genes involved in numerous physiologic and developmental
processes including cellular proliferation, cell cycle progression,
and apoptosis (reviewed in Lee and Ambros, 2001; Cheng et al.,
2005;Hayashita et al., 2005; Ivanovska et al., 2008).AlteredmiRNA
expression has been implicated in the pathology of leukemia,
where some miRNAs are proposed to function either as tumor
suppressor genes (TS) or oncogenes (Table 1; Esquela-Kerscher
and Slack, 2006).
miRNAs IN AML
Acute myeloid leukemia is characterized by the abnormal prolif-
eration and accumulation of immature myeloblasts in the bone
marrow and blood. Diagnosis is based on the presence of malig-
nant blasts in the bone marrow as well as distinctive translo-
cations and gene mutations. AML represents a group of het-
erogeneous disorders with striking differences in survival based
on cytogenetics, prognostic gene mutations, and age and has an
average long-term overall survival (OS) rate of approximately 25–
60% depending on the above characteristics in patients over age
55 (Heerema-McKenney and Arber, 2009; http://seer.cancer.gov,
accessed September 24, 2011).
Golub et al. (1999) ﬁrst demonstrated that expression proﬁling
of protein-encoding genes could distinguish AML from ALL, pio-
neering the way for expression-based diagnostic approaches. The
advent of miRNA expression proﬁling further distinguished AML
from ALL and has been used to explore possible associations of
miRNAswith regard to diagnosis,prognosis, and response to treat-
ment (Calin andCroce, 2006;Mi et al., 2007). Garzon et al. (2008b)
reported that the expression of miR-29 family member miR-29b is
often down-regulated in primary AML with respect to bone mar-
row CD34+ progenitors. miR-29b directly targets the 3′UTR of
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FIGURE 1 | (A) Regulatory microRNA mechanisms in leukemia. (A1)
Perfect base complementarity between miRNA and target mRNA can lead
to target mRNA degradation. (A2) Imperfect base complementarity
between miRNA and target mRNA can lead to mRNA translational
repression. (B) Currently hypothesized mechanisms of lncRNA regulation
in leukemia. (B1) Recruitment of PcGs leads to stable repression, although
the mechanism of lncRNA association with the target sequence is
unknown. (B2) lncRNAs can inﬂuence miRNA cluster transcriptional
activity, and can be post-transcriptionally regulated by miRNAs. (B3)
Activator lncRNAs enhance transcriptional or binding afﬁnity of transcription
factors, although the mechanism of lncRNA association with the target
sequence is unknown.
DNA methyltransferases DNMT3a and DNMT3b and indirectly
targets DNMT1 via negative regulation of SP1, a transactivator
of DNMT1. Down-regulation of the methyltransferases caused by
forced expression of miR-29b leads to altered DNA methylation
and subsequent repression of TS genes such as p15INK4b and ESR1
often observed in myeloid leukemogenesis (Garzon et al., 2009b).
Restoration of miR-29b increases sensitivity to the hypomethy-
lating agent, decitabine, in patients with AML over age 60 (Blum
et al., 2010). Forced expression of miR-29b in AML cell lines and
primary AML samples reduces cell growth and induces apoptosis,
indicative of its TS activity in acute leukemia. Additional support
was provided by the dramatic reduction of tumors in a xenograft
leukemia model in response to miR-29b over-expression. Follow-
ing miR-29b expression, gene expression analysis of the AML cell
line K562 showed that miR-29b, along with miR-29a, target path-
ways involved with cell cycle, proliferation, and apoptosis (Garzon
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Table 1 | Characteristics of discussed ncRNAsa.
ncRNA(s) ncRNA class Target Disease association Clinical relevance Citation





Garzon et al. (2009b)
miR-126/126* miRNA N/A AML Diagnostic: CBF Li et al. (2008)
miR-224, -368, -382 miRNA N/A AML Diagnostic: t (15; 17) Li et al. (2008)
miR-126, -126*, -224, -368, -382,
-17-5p, -20a
miRNA N/A AML Diagnostic:
MLL-rearrangement
Li et al. (2008)
miR-21 miRNA PTEN AML Diagnostic: t (6; 11) vs.
t (9; 11), prognostic
Garzon et al. (2008a)
miR-29b miRNA TCL1 AML Diagnostic: balanced
11q23 translocations;
potentially therapeutic
Garzon et al. (2008a)
miR-155 miRNA Unknown in AML AML Diagnostic: FLT3–ITD
mutations
Garzon et al. (2008a)
miR-199a, -191 miRNA N/A AML Prognostic Garzon et al. (2008a)
miR-181 miRNA TLR and IL1-β AML Prognostic Marcucci et al. (2008)
(miR-128a, -128b) vs. (miR-223,
let-7b]
miRNA N/A AML vs. ALL Diagnostic Mi et al. (2007)
miR-18a, -532, -218, -625, 193a,
-638, -550, -663
miRNA N/A ALL Prognostic Zhang et al. (2009a)
miR-143 miRNA MLL–AF4 ALL Prognostic, potentially
therapeutic
Dou et al. (2011)
miR-15a, -16-1 miRNA Bcl2 CLL Potentially therapeutic Bandi et al. (2009b)
miR-29, -181 miRNA TCL1 CLL Prognostic, potentially
therapeutic
Pekarsky et al. (2006)
miR-15a, -195, -221, -23b, -155,
-223, -29a, -24, -29b, -146, -16,
-16-2, -29c
miRNA N/A CLL Diagnostic: expressed
ZAP-70 and unmutated
IgVH vs. no ZAP-70
and mutated IgVH
San Jose-Eneriz et al.
(2009)
miR-7, -23a, -26a, -29a, -29c, -
30b, -30c, -100, -126, -134, -141,
-183, -196b, -199a, -224, -362,
-422b, 520a, -191
miRNA N/A CML Predictive response to
therapy
San Jose-Eneriz et al.
(2009)
ANRIL, p15AS Antisense p15 AML/ALL Diagnostic, potentially
prognostic
Yu et al. (2008);
Iacobucci et al. (2011)
lincRNA-p21 lincRNA BCR-ABL Potentially CML Potentially therapeutic Notari et al. (2006);
Du et al. (2010)
MEG3 lincRNA p53, GDF15 MDS/AML Prognostic Benetatos et al.
(2009)
CombinedT-UCR and miR proﬁle UCR N/A CLL/AML Diagnostic: tumor
type; prognostic
Calin et al. (2007)
Dleu2 lincRNA miR-15a/16 CLL Diagnostic, potentially
therapeutic
Migliazza et al. (2001);
Lerner et al. (2009)
HOTAIRM1 Antisense HOXA1,HOXA4, CD11b,
CD18
Hematopoietic regulator Potentially therapeutic Zhang et al. (2009b)
EGO Antisense MBP, EDN Hematopoietic regulator Potentially therapeutic Wagner et al. (2007)
lincRNA-a7 lncRNA SCL/TAL1 Hematopoietic regulator Potentially therapeutic Ørom et al. (2010)
ªNon-coding RNAs having different diagnostic or therapeutic roles in different leukemia subtypes are listed separately.
et al., 2009a). Together these data suggest that synthetic miR-29b
oligonucleotides could potentially serve as a therapeutic approach
in AML.
Just as numerous groups have identiﬁed mRNA signatures
distinguishing AML subclasses, several groups have associated
miRNA signatures with cytogenetic abnormalities and predictors
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of outcome in AML (Bullinger et al., 2004; Valk et al., 2004).
Li et al. reported that miRNA expression signatures accurately
discriminate between AMLs with the common translocations
t (15; 17), t (8; 21), and inv(16), all of which represent favor-
able prognosis rearrangements that result in the disruption of
core-binding factors (CBF). Expression of two (miR-126/126∗),
three (miR-224, -368, and -382), and seven (miR-126, -126∗, -
224, -368, -382, -17-5p, and -20a) miRNAs distinguishes CBF
t (8; 21) and inv16, t (15; 17) and MLL-rearrangement AMLs,
respectively, from one another (Li et al., 2008). Up-regulation of
miR-21 distinguishes AMLs with t (6; 11) from those with t (9; 11),
while down-modulation of miR-29 correlateswith balanced 11q23
translocations. miR-155 shows increased expression in patients
with AML characterized by FLT3–ITD mutations (Garzon et al.,
2008a).
Expression patterns of miRNAs are also associated with prog-
nosis. Marcucci et al. (2008) have associated a worse prog-
nosis in patients with t (6; 11) who display increased expres-
sion of miR-21, an inhibitor of the TS PTEN. This group
has also shown that patients with AML that express ele-
vated miR-199a and -191 have a signiﬁcantly lower OS and
event-free survival (Garzon et al., 2008a). The miR-181 fam-
ily has been shown to contribute to an aggressive AML phe-
notype through mechanisms associated with the activation of
pathways controlled by toll-like receptors and interleukin-1β
(Marcucci et al., 2008).
miRNAs IN ALL
Acute lymphoblastic leukemia represents a heterogeneous group
of disorders that result in the malignant transformation of lym-
phoblasts at various stages of differentiation. Although more
common in children, ALL also occurs in adults, with a shift from
childhood-prevalent to adulthood-prevalent subtypes during ado-
lescence. A diagnosis of ALL occurs when blood and bone marrow
samples show a large number of abnormal lymphocyte blasts.
Treatment options are based on ALL subtype and prognostic
factors such as age.
Mi et al. (2007) have shown that expression signatures of as
few as two miRNAs can discriminate ALL from AML; miR-128a
and -128b were signiﬁcantly higher in ALL, whereas miR-223
and let-7b were expressed at signiﬁcantly higher levels in AML.
This study also demonstrated that lineage discriminating miRNAs
could differentiate ALL samples from AML samples even when
both leukemias displayed the same translocation/fusion events
such as t (11; 19)(q23; p13.3)/MLL–ENL (Mi et al., 2007). Zhang
et al. identiﬁed an 8-miRNA-expression proﬁle (miR-18a, -532,
-218, -625, -193a, -638, -550, and -663) that differentiates good
from poor steroid response in pediatric ALL. miRNA expression
signatures were also able to identify relapse and non-relapse pedi-
atric cases (Zhang et al., 2009a). miR-143 has been shown to
negatively regulate the MLL–AF4 fusion protein, a product of the
translocation t (4; 11)(q21; q23), which confers poorer prognosis
compared to other MLL arrangements. Restoration of miR-143 in
MLL–AF4-positive cells induced apoptosis by reducing MLL–AF4
fusion protein levels, suggesting that forced expression of miR-128
could serve as a therapeutic agent in MLL–AF4 ALL (Dou et al.,
2011).
miRNAs IN CLL
Chronic lymphocytic leukemia, themost common leukemia found
in adults, results from immature, malignant resting B cell lym-
phocytes overexpressing the anti-apoptotic B cell lymphoma 2
(Bcl2) protein and accumulating in the bone marrow and the
blood (Cimmino et al., 2005). Of those diagnosed with CLL,
most are over the age of 50. CLL exhibits clinical heterogeneity
as marked by the observation that some patients present with
aggressive leukemia requiring immediate treatment while others
require no intervention for many years (Li et al., 2011).
The ﬁrst demonstration of miRNA association with pathogen-
esis was discovered in CLL (Calin et al., 2002). The Croce group
showed that miR-15a and -16 reside in the fragile chromosomal
band 13q14, which is deleted in more than half of CLL cases, as
well as some prostate tumor and retinoblastoma samples (Chen
et al., 2001; Kivelä et al., 2003). They went on to show that miR-15a
and -16 negatively regulate cell growth and cell cycle progression
(Calin et al., 2002). Additionally, over-expression of these miRNAs
has been shown to repress Bcl2 expression and induce apoptosis
in a leukemic cell line model, indicating a potential therapeutic
role for miR-15a and -16 in the treatment of Bcl2-overexpressing
tumors (Bandi et al., 2009a).
Two markers of aggressive CLL include up-regulated 70-kDa
zeta-associated protein (ZAP-70) and unmutated immunoglobu-
lin variable genes (IgVH).When these factors are expressed at high
levels they are associated with high levels of TCL1, an oncogene
that co-activates the anti-apoptotic oncoprotein AKT and aids in
regulatory pathways involved in cell survival and death. miR-29
and -181 have been shown to negatively regulate TCL1. Clini-
cal CLL samples show miR-29 and -181 expression is inversely
related to TCL1 expression, suggesting that these miRNAs could
potentially serve as prognostic markers of CLL progression and
as therapeutic agents in aggressive forms of TCL1-overexpressing
CLL (Pekarsky et al., 2006). Calin et al. (2005) demonstrated that
13 miRNAs (miR-15a, -195, -221, -23b, -155, -223, -29a, -24, -29b,
-146, -16, -16-2, and -29c) could discriminate between patients
expressing ZAP-70 and unmutated IgVH and those not express-
ing ZAP-70 and mutated IgVH, thereby distinguishing aggressive
from indolent CLL.
miRNAs IN CML
Chronic myeloid leukemia is a malignant clonal stem cell dis-
order characterized by an increase of mature granulocytes in the
bonemarrow and blood. It often expresses the constitutively active
BCR-ABL tyrosine kinase formed by a translocation that links
Abl1 on chromosomal band 9q34 to a portion of BCR on chro-
mosomal band 22q11. CML is often suspected on the basis an
extremely elevated white blood cell count with maturation of
white blood cells and few or no leukemic blasts. Treatment and
prognosis depend primarily on the phase of CML, i.e., whether
in chronic, accelerated, or blast crisis. The development of the
BCR-ABL1 kinase inhibitor, imatinib mesylate, as well as other
Bcr–Abl inhibitors, has signiﬁcantly improved treatment and out-
come of patients with CML (Kantarjian et al., 2002). Jose-Eneriz
et al. (2009) identiﬁed 19 miRNAs (18 up-regulated: miR-7, -23a,
-26a, -29a, -29c, -30b, -30c, -100, -126, -134, -141, -183, -196b,
-199a, -224, -362, -422b, -520a, and 1 down-regulated: miR-191)
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that are differentially expressed between imatinib resistant and
responder samples.
LONG NON-CODING RNAs IN LEUKEMIA
Long non-coding RNAs are ncRNAs greater than 200 nucleotides
long, transcribed by RNA polymerase II or III, and can account
for nearly 60% of all non-ribosomal and non-mitochondrial RNA
in human cells (Kapranov et al., 2010). LncRNAs are involved in
transcriptional silencing, chromatin remodeling, and gene acti-
vation (reviewed in Huarte and Rinn, 2010; Gibb et al., 2011)
and originate from many chromosomal environments, includ-
ing antisense to protein-coding genes, intergenic DNA (termed
“lincRNAs” for long intergenic non-coding RNAs’), and from
ultraconserved regions (Carninci et al., 2005). Excluding the latter,
only a few lncRNAprimary sequences are evolutionarily conserved
(Guttman et al., 2009; Baker, 2011). In contrast to miRNAs, sev-
eral cases have shown that conservation of secondary structure is
more important to preserving ncRNA function than nucleotide
sequence (Yap et al., 2010). Although lncRNAs in leukemia are not
as extensively characterized as they are in some other tumor types,
recent progress has identiﬁed several high proﬁle targets that could
alter how lncRNAs are viewed in terms of leukemia development,
classiﬁcation, and therapeutic targeting.
SUPPRESSORS OF TUMOR SUPPRESSORS ARE ONCOGENES
The INK4A–ARF–INK4B locus is deregulated in up to 40% of
human cancers (Sherr, 1998; Kim and Sharpless, 2006). In addi-
tion to p15INK4b, p14ARF, and p16INK4a, TS genes interact closely
with p53 and Rb to regulate cell cycle progression (Bandi et al.,
2009a). Pasmant et al. identiﬁed a polyadenylated lncRNA that
was transcribed antisense to p15INK4b. The full-length transcript,
ANRIL (antisense ncRNAs in the INK4 locus) has several iso-
forms (Pasmant et al., 2007). The p15AS variant, isolated from
two AML cell lines, was signiﬁcantly up-regulated in 11 of 16
AML and ALL primary samples (Yu et al., 2008). The authors
demonstrated that p15AS was responsible for Dicer-independent
silencing of p15INK4b by altering H3K9me2 and H3K4me2 levels
at both endogenous and exogenous p15INK4b promoters. EZH2
and SUZ12 were required for stable silencing of p15INK4b, even
after p15AS repression, indicating the likely recruitment of the
polycomb repressive complex 2 (PRC2). Other reports demon-
strated ANRIL-CBX7 interacts with either di- or tri-methylated
H3K27, implying that ANRIL-mediated silencing works through
both PRC1 and PRC2 complexes (Figure 1; Group et al., 2005;
Kotake et al., 2011; Margueron and Reinberg, 2011). A study
by Iacobucci et al. (2011) involving acute leukemia and normal
peripheral blood cells showed a statistically signiﬁcant association
between anANRILnucleotide polymorphismandALLphenotype,
demonstrating the importance of regulated ANRIL expression in
primary leukemia.
Acting downstream of ANRIL, lincRNA-p21 is a 3.1-kb tran-
script induced by p53 expression that represses cellular pro-
liferation by both p53-dependent and independent mecha-
nisms (Huarte et al., 2010). LincRNA-p21 contains two canon-
ical p53 binding sites in a promoter distinct from its clos-
est neighbor, CDNK1A. Independent knock-down of either
p53 or lincRNA-p21 produces signiﬁcantly overlapping gene set
enrichments (p< 10−200), implying at least a partial overlap of
apoptosis-induction mechanisms. Interestingly, in p53−/− cell
lines, lincRNA-p21 cannot direct proper localization and function
of the pre-mRNA binding protein hnRNP-K (Huarte et al., 2010).
Although these functional studies were done in mouse embry-
onic ﬁbroblasts and human lung carcinoma cell lines, two reports
demonstrate that BCR-ABL stimulates hnRNP-K expression and
stability, subsequently promoting tumor progression (Notari et al.,
2006; Du et al., 2010). Although the activity of lincRNA-p21 in
acute or chronic leukemia is currently unknown, these data suggest
that further work in CML is warranted.
p53-INTERACTING TUMOR SUPPRESSOR lncRNAs
A second p53-regulating lincRNA, MEG3, was highlighted in
human malignancies when investigators reported high expression
levels in normal gonadotrophs and severely reduced expression in
tumor-derived gonadotroph cells (Zhang et al., 2003). Forcing re-
expression of MEG3 in HCT-116 cells leads to p53 accumulation
and inhibition of cellular proliferation, indicative of a high-level
regulator of p53-dependent TS activities (Zhang et al., 2003; Zhou
et al., 2007). Although MEG3 isoforms can contain several small
open reading frames, they are not required for p53-mediated cellu-
lar activities (Zhou et al., 2007; Zhang et al., 2010a). Instead,MEG3
secondary structure is critical to maintaining function, including
down-regulation of MDM2 expression and enhanced p53 binding
to a speciﬁc subset of gene promoters, including GDF15 (Figure 1;
Zhang et al., 2010a). Of interest,MEG3 can suppress cell growth in
p53null cells, indicating p53-independent activities as well (Zhou
et al., 2007).
Expression of theMEG3-DLK1 locus is tightly regulated by two
differentially methylated regions (DMRs), which are hypermethy-
lated in a subset of solid tumors and suppress MEG3 expression
(Kagami et al., 2010; Astuti et al., 2005). Benetatos et al. (2009)
examined a cohort of 85 patients with either myelodysplastic syn-
drome (MDS) or AML. They found that 48% (20/42) of patients
withAML displayed aberrant hypermethylation of the MEG3 pro-
moter, which signiﬁcantly correlated with decreased OS (HR 1.98,
p = 0.04). In MDS, 35% (15/43) of patients displayed aberrant
hypermethylation, a result that trended toward decreased survival
but was not quite signiﬁcant (HR 2.15, p = 0.072; Benetatos et al.,
2009). An independent assessment of 40AML samples by a second
group conﬁrmed aberrant methylation in the MEG3-associated
DMRs in AML samples, but not in normal controls (Khoury
et al., 2010). Importantly, neither study showed MEG3 hyper-
methylation to be associated with karyotype or disease subtype
(Benetatos et al., 2009).Although additional studies will be needed
to determine the functional role of MEG3 in leukemia, the impor-
tance of its interactions with MDM2, p53, and GDF15, as well
as p16 in pituitary carcinomas, will likely demonstrate a role for
MEG3 in leukemia (Zhang et al., 2010b).
ncRNA–ncRNA REGULATION: TRANSCRIBED
ULTRACONSERVED REGIONS AND HOST GENES
Within the human genome, 481 transcribed genomic segments
have been identiﬁed that are 100% conserved between ortholo-
gous regions in the human, mouse, and rat (Bejerano et al., 2004;
Calin et al., 2007). Of these “transcribed ultraconserved regions”
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(T-UCRs), 39% are contained within intergenic sequences and
43% are intronic; the remainder are exonic or exon-overlapping
(Mestdagh et al., 2010). Like miRNAs, T-UCR locations are closely
associated with genomic fragile sites and ubiquitously expressed
T-UCRs are frequently associated with cancer-associated genomic
regions (CAGRs; Calin et al., 2004, 2007). Microarray analysis has
shown that T-UCRs differentially expressed in human malignan-
cies are highly likely to be associated with CAGRs of that tumor
type (Calin et al., 2007).
Transcribed ultraconserved regions expression has been used
to predict disease outcome in both CLL and neuroblastoma sam-
ples (Calin et al., 2007). In a survey of 133 cancers and 22 normal
tissues, a proﬁle of 19 T-UCRs (8 up- and 11 down-regulated)
could differentiate between normal, CLL, colorectal, and hepato-
carcinoma samples (Calin et al., 2007). This study also showed that
the expression of ﬁve T-UCRs (three intronic and two intergenic)
could divide a CLL cohort into two prognostic groups, previ-
ously deﬁned by low (favorable) vs. high (poor) ZAP-70 expres-
sion (Calin et al., 2007). Expression of these diagnostic T-UCRs
negatively correlated with the previously deﬁned CLL miRNA sig-
nature, suggesting a mechanism for miRNA regulation of these
T-UCRs (Calin et al., 2005). Of the diagnostic T-UCR proﬁle,
three (uc.160, uc.346A, and uc.348) contain miRNAs recognition
sites, including targeting bymiR-155::miR-24:: andmiR-29 (Calin
et al., 2005). Repressive activity of miR-155 was conﬁrmed in
an in vitro assay, while the negative correlations were observed
between miR-155?uc.346A and miR-24?uc pairings; 160 were vali-
dated in the aforementioned diagnostic cohort (Calin et al., 2007).
miR-155 over-expression was identiﬁed in CLL, while in AML its
up-regulation was associated with expanded bone marrow gran-
ulocyte and monocyte proliferation (reviewed in Faraoni et al.,
2009) and miR-24 loss-of-function has been linked to methotrex-
ate resistance in HCT-116 cells (Mishra et al., 2009). Interestingly,
miR-29a has also been shown to regulate MEG3 expression in
hepatocarcinoma cell lines (Braconi et al., 2011). Although it is
currently unknown whether miRNAs repress T-UCRs, or whether
the altered expression of the T-UCRs affects the primary target of
the leukemia-associated miRNAs, it is clear that careful regulation
of these two ncRNA species is critical to understanding the dis-
ease state and for developing ncRNA-associated classiﬁcation or
ncRNA-directed targeted therapy. In addition to miRNA regula-
tion, differential methylation of T-UCR-associated CpG islands
(CGI) may also control expression. In a study of 15 leukemia
cell lines and 64 primary leukemia samples, differential methy-
lation was seen at three of these CGI (∼60% in cell lines and
approximately 18% in primary samples), although the relevance
of CGI-mediated hypermethylation to leukemia etiology remains
unclear (Lujambio et al., 2010). A much larger cohort will need to
be investigated before diagnostic implications can be veriﬁed.
Long non-coding RNAs targeting bymiRNAs is only one exam-
ple of ncRNA-ncRNA regulation. Deleted in leukemia 2 (Dleu2)
is an lncRNA transcribed from 13q14 (Liu et al., 1997; Migliazza
et al., 2001). The Myc-repressed Dleu2 transcript is a host gene for
the miR-15a/miR-16-1 cluster, providing the primary transcript
from which miR-15a and miR-16-1 are processed (Figure 1; Klein
et al., 2010). While de-regulation of these two miRNAs has long
been associated with CLL, deletion-mapping studies have demon-
strated that theDleu2 transcript is frequently disrupted in CLL cell
line, and increased expression of this gene leads to reduced prolif-
eration and clonogenicity (Lerner et al., 2009). Although further
analysis is needed in order to validate these observations, Dleu2
serves as an important example of the intricate co-regulation of
lncRNA and miRNAs.
HEMATOPOIETIC REGULATOR lncRNAs AS POTENTIAL
ONCOGENIC GENES
Newly discovered lncRNAs are being characterized at a rapid
pace. In hematopoiesis, the antisense lincRNA, HOTAIRM1, has
recently been identiﬁed as an essential regulator of myeloid cell dif-
ferentiation. This lincRNA is transcribed from within the HOXA
cluster and regulates HOXA1, HOXA4, CD11b, and CD18 during
retinoic acid-induced differentiation of an acute promyelocytic
leukemia cell line (Zhang et al., 2009b). EGO is expressed during
eosinophil development and is essential for major basic protein
and eosinophil-derived neurotoxin mRNA expression (Wagner
et al., 2007). Ørom et al. (2010) identiﬁed several lncRNA acti-
vators, one of which strongly induced expression of SCL/TAL1.
Although these lncRNAs have not yet been associated with
hematopoietic malignancies, such critical regulators of cell fate
are likely to be identiﬁed as potent regulators of tumorigenicity.
CONCLUSION
It has become evident in recent years that the de-regulation of
miRNAs and lncRNAs plays a critical role in malignant trans-
formation, tumor cell behavior and, in particular, hematologic
malignancies. These ncRNAs could prove to be increasingly useful
in the development of much needed novel diagnostic, prognostic,
and therapeutic strategies for acute and chronic leukemias.
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